Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?
about
Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaBitter taste receptors on airway smooth muscle as targets for novel bronchodilatorsAntithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradoxBitter taste receptor function in asthmatic and nonasthmatic human airway smooth muscle cells.Bitter taste receptors in the wrong place: novel airway smooth muscle targets for treating asthma.Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthmaThree generations of ongoing controversies concerning the use of short acting beta-agonist therapy in asthma: a review.Management of the acute exacerbation of asthma.Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.Pleiotropic Effects of Bitter Taste Receptors on [Ca2+]i Mobilization, Hyperpolarization, and Relaxation of Human Airway Smooth Muscle Cells.Polycyclic aromatic hydrocarbons impair function of β2-adrenergic receptors in airway epithelial and smooth muscle cellsRelative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats.Long-Acting Beta Agonists Enhance Allergic Airway DiseaseThe use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysisTAS2R activation promotes airway smooth muscle relaxation despite β(2)-adrenergic receptor tachyphylaxis.The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studySelf-management of acute asthma among low-income urban adults.Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitization in airway smooth muscle.Therapeutic management of allergic diseases.Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthmaAn update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids.Combination budesonide/formoterol inhaler as maintenance and reliever therapy in Māori with asthma.Heterogeneity of transcription factor expression and regulation in human airway epithelial and smooth muscle cells.Transcriptional response to persistent beta2-adrenergic receptor signaling reveals regulation of phospholamban, which alters airway contractility.Coupling of Airway Smooth Muscle Bitter Taste Receptors to Intracellular Signaling and Relaxation Is via Gαi1,2,3.Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta2-adrenoceptor agonist exposure.Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization.Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma.Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions.Divergence in NK cell and cyclic AMP regulation of T cell CD40L expression in asthmatic subjects.Prolonged heterologous beta2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction.Identification of patterns of factors preceding severe or life-threatening asthma exacerbations in a nationwide study.Wheezing in relation to atopy and environmental factors in Estonian and Swedish schoolchildren.Asthma Mortality and Long-Acting Beta2-Agonists in Five Major European Countries, 1994–2004
P2860
Q24246441-2F916E6D-80DE-4410-B3AF-261ADDF8D6B2Q24247926-62325E38-300A-4C9A-AA6F-A8371F532469Q26830082-F5ADA6F1-C817-4E8C-8D32-734603E1749CQ28507610-B5A44710-957B-415C-92BA-635ECDB54C9EQ33799618-1D450AAB-B950-4D2D-BD92-DC9C7E7DFC7CQ33957832-35B7329D-C5D6-40EE-A313-75984FE42F6BQ34698968-FAC13E6A-F06D-49B7-9F01-E8F3EE9C33C3Q34747731-6659E570-85FE-470E-8679-001DDA2857AAQ35568521-27589A32-1DE3-4DE4-8709-00AE18C4F638Q35627925-EDAFBFB8-9DCE-4AE2-810F-C4D8FFE34523Q35677528-24AFC0D1-E1FE-4B54-93D4-C654368C060EQ35684897-9C60D4AE-5B77-45EC-973A-179157B032F1Q35689566-50FF8E87-F58A-479E-8AFC-667FD6A79D50Q35852118-61FD055E-D527-4617-B798-D3C2E24DFFEDQ35939347-A6E57367-13CB-4B55-B6CA-AD6132497F97Q36178070-04B2892A-A4E1-4BE7-9504-7684512779E6Q36477727-03AC7D28-C4AB-4EED-A2D7-2C75DAB77A84Q37362256-51755B13-4E1E-4BE6-95C5-60DFA52E9786Q37406409-C016E44A-AAB3-4864-998E-DC7D50F7E29AQ37550543-17D88F15-9348-4D4F-A5E2-C193DBC3FA31Q37694255-4047F9AC-D797-4A14-B43B-ACBFE7B42790Q37735203-3CABF194-6991-418D-97D7-E91D669B2661Q38217022-F5E47476-0E42-4C65-9C4C-FB64E1F6DA7CQ38301015-B7351B48-FF91-4047-BFE5-17BA5DA6E6FFQ38311375-9F78432B-09D2-4BF8-B6B3-E95D7F9DDB50Q38987293-ADF3A05C-88F2-4427-AC1C-6A4E849205FCQ40447823-A1912F45-6A3B-44FD-929D-85476D267F7CQ41852598-A13C418C-35C9-4CD7-83DB-50EBF719DF82Q42572291-7742A1A3-36A3-4B39-82EF-D6D28FABA495Q44230025-D763355B-D2FC-4334-9604-B7B80D98DBB6Q44576446-82D62461-0D63-43C6-B0A1-9F5010600968Q46687772-F208A416-5B32-4A68-812D-04A6279DAC72Q47690169-2B837018-5360-43A6-AA5A-5B04A78C665EQ53319785-65D6DD33-038F-4729-9166-1353E16C23C1Q57559559-89E36157-1556-4A93-9577-CA5EBA28AFC6
P2860
Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Beta-agonists: what is the evi ...... sthma morbidity and mortality?
@ast
Beta-agonists: what is the evi ...... sthma morbidity and mortality?
@en
type
label
Beta-agonists: what is the evi ...... sthma morbidity and mortality?
@ast
Beta-agonists: what is the evi ...... sthma morbidity and mortality?
@en
prefLabel
Beta-agonists: what is the evi ...... sthma morbidity and mortality?
@ast
Beta-agonists: what is the evi ...... sthma morbidity and mortality?
@en
P1476
Beta-agonists: what is the evi ...... sthma morbidity and mortality?
@en
P2093
P304
P356
10.1016/S0091-6749(99)70270-8
P407
P433
P577
1999-08-01T00:00:00Z